Form 4: Kestra Medical CEO Sells 15,000 Shares Under 10b5-1 Plan

Kestra Medical Technologies CEO Brian Daniel Webster sold 15,000 common shares for approximately $390,000 through a pre-arranged trading plan.

Summary

• Brian Daniel Webster, President and Chief Executive Officer of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), reported sales of common shares.
• The transactions occurred on February 17, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• A total of 11,635 common shares were sold at a weighted average price of $25.3937 per share, with prices ranging from $25.0150 to $26.0100.
• An additional 3,272 common shares were sold at a weighted average price of $26.2947 per share, with prices ranging from $26.0200 to $26.9998.
• A further 93 common shares were sold at a weighted average price of $27.1789 per share, with prices ranging from $27.0771 to $27.1800.
• Following these transactions, Brian Daniel Webster beneficially owns 379,786 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, these sales were conducted under a pre-established 10b5-1 plan, which mitigates concerns about opportunistic trading based on non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

Industry Context

StockSavvy.ai notes that insider sales under a Rule 10b5-1 plan are common practice for executives to diversify holdings and manage personal finances without concerns of trading on material non-public information. These plans are typically set up well in advance and do not necessarily reflect a change in management's outlook on the company's prospects, unlike unscheduled sales.

Stakeholder Impact

• Shareholders may observe a slight reduction in the CEO's direct equity stake, but the pre-planned nature of the sales should alleviate concerns about management's confidence in the company.

Key Dates

Recommendation

The insider sales are part of a pre-arranged 10b5-1 plan, which suggests a routine financial management decision rather than a signal of deteriorating company fundamentals. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should 'hold' and consider broader company performance and market conditions.

Keywords

Kestra Medical Technologies, KMTS, Insider Trading, Form 4, Stock Sale, CEO, Brian Daniel Webster, 10b5-1 Plan